Outlook Therapeutics swings to Q1 net loss

Outlook Therapeutics

17/02/2026 13:14

Overview

Biopharmaceutical company swings to fiscal Q1 net loss

Adjusted net loss for fiscal Q1 improves yr/yr

Revenue impacted by UK distributor product returns

Outlook

Outlook Therapeutics plans additional European launches of LYTENAVA in 2026 and 2027

Company submitted Type A meeting request to FDA for ONS-5010

Outlook Therapeutics aims to partner with companies in Europe, Latin America, and Asia

Result Drivers

EUROPEAN SALES GROWTH - LYTENAVA unit sales in Europe more than doubled in Q1, driven by growing adoption post-launch

REVENUE IMPACT - Revenue negatively impacted by increased returns reserve due to short-dated product shipments in UK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Miss
-$0.22
-$0.18 (2 Analysts)
Q1 EPS
-$0.38
Q1 Net Income
-$23.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Outlook Therapeutics Inc is $5.50, about 1,022.4% above its February 13 closing price of $0.49

Press Release: ID:nGNXbMvHNB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)